Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer’s Reinhardt Returning To Novartis To Replace Departing Vasella

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.

You may also be interested in...



CHMP Rejects Serelaxin But Clears Albiglutide, Riociguat And Lurasidone

Europe’s top medical advisory panel turns down a new acute heart failure therapy from Novartis, but gives positive opinions to three other new active substances, from GlaxoSmithKline, Bayer and Takeda, following its Jan. 20-23 meeting.

Bayer Taps Pfizer Emerging Markets Head To Lead Health Care Division

Pfizer’s Olivier Brandicourt, who has specialized in emerging markets and infectious diseases, inherits Bayer’s health care division, which is in the midst of several product launches and has few near-term patent expirations. Bayer has one of the largest exposures to emerging markets among large pharma companies.

Bayer Names Pfizer’s Brandicourt Healthcare Division CEO

The broadly experienced pharmaceutical executive – who has specialized particularly in emerging markets and infectious diseases – inherits a healthcare division that is in the midst of several product launches and has few near-term patent expirees.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel